TScan Therapeutics, Inc. — Director's Dealing 2021

Dec 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TScan Therapeutics, Inc. (TCRX)
CIK: 0001783328
Period of Report: 2021-12-23

Reporting Person: SOUTHWELL DAVID P (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-23	Voting Common Stock	M	48670	$1.97	Acquired	146569	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-23	Stock Option (Right to Buy)	$1.97	M	48670	Disposed	2029-02-04	Voting Common Stock (48670)	Direct

Footnotes

F1: The shares originally subject to this option vested over 4 years of service following October 9, 2018, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. In addition, all of the shares subject to this option shall vest and become fully exercisable upon a Change of Control (as defined in the option agreement).